menu 1
menu 2
menu 3

  Cancer Studies

  Sickle Cell Anemia

  Cystic Fibrosis

  Urea Cycle Disorder

  Benign Prostate Hyperplasia

  Adrenoleukodystrophy

  Neurological/Neuromuscular Disorders

  Multiple Sclerosis

  Kidney Diseases

  Amyotrophic Lateral Sclerosis

  Brain Disorders

  Huntington's Disease

  Spinal Muscular Atrophy

menu 4
 

Sodium Phenylbutyrate is an investigational drug and has been used in clinical trials and studies worldwide since 1987. The trials and studies for Sodium Phenylbutyrate have been sponsored and/or supported by grants from such organizations as the National Institutes of Health – National Cancer Institute, the Cystic Fibrosis Foundation, the Heart and Stroke Foundation of Québec, the Associations ASAMSI, the United States Leukodystrophy Foundation, The Johns Hopkins Hospital Pediatric Clinical Research Unit, the Israel Science Foundation, the Cooley’s Anemia Foundation, University of Toronto, Canada, the Aplastic Anemia and MDS International Foundation, the U.S. Navy, the Brain Tumor Foundation, the National Breast Cancer Foundation, the Australian Cancer Foundation, the Leukemia and Lymphoma Society of America, the Austrian National Bank, the Johns Hopkins General Clinical Research Center Grant, the UMDNJ Foundation, the Clayton Foundation for Research, the Gaetano Fichera Fellowship, Associazione Italiana per la Ricerca sol Cancro, the Samuel Waxman Cancer Research Foundation, the Jefferess Foundation, the American Cancer Foundation and numerous other government and private organizations and foundation.

Sodium Phenylbutyrate has been studied for use in treatment of diseases such as cancer (malignant mesotheioma, myelodysplastic syndromes and acute myeloid leukemia, refractory solid tumor malignancies, refractory high grade astrocytomas (HGA), colon cancer, colorectal cancer, breast cancer, prostate cancer, pancreatic carcinoma, nasopharyngeal carcinoma, recurrent malignant glioma, etc.), cystic fibrosis, sickle cell anemia, beta-thalasemia, urea cycle disorder, benign prostate hyperplasia, adrenolucodystrophy, neuromuscular disorders and others.

Studies of Sodium Phenylbutyrate have been published in such journals as: International Journal of Oncology, Journal of Neuro-Oncology, International Journal of Cancer, Molecular Cancer Therapeutics, Cancer Research, Clinical Cancer Research, Journal of Pharmaceutical Sciences, Neoplasa, Cancer Chemother Pharmacol, Clinical & Experimental Metastasis, Leukemia, The Journal of Clinical Endocrinology & Metabolism, Cancer Letters (Elsevier), Blood, Anticancer Research, Journal of Clinical Oncology, Journal of the National Cancer Institute, and other major journals.

Scandinavian Formulas, Inc.
140 East Church Street
Sellersville PA 18960

215-453-2507 Ext. 104 - Tel

800-688-2276 - USA Only

215-257-9781 - Fax

 

 

 

 

 

 

DISCLAIMER:The information presented is intended for educational purposes for health professionals and practitioners, and is obtained from published research. It is not intended to be prescriptive nor to replace the care of a licensed health professional in the diagnosis and treatment of illness.
Print this page